Molecule
Teprotumumab is an insulin-like growth factor-1 receptor inhibitor indicated for the treatment of Thyroid Eye Disease regardless of Thyroid Eye Disease activity or duration. It is available as powder for injection for intravenous use. MedsAcross supplies Teprotumumab for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
TEPEZZA is indicated for the treatment of Thyroid Eye Disease regardless of Thyroid Eye Disease activity or duration. TEPEZZA is an insulin-like growth factor-1 receptor inhibitor indicated for the treatment of Thyroid Eye Disease regardless of Thyroid Eye Disease activity or duration
Source: US FDA prescribing information
Teprotumumab-trbw's mechanism of action in patients with Thyroid Eye Disease has not been fully characterized. Teprotumumab-trbw binds to IGF-1R and blocks its activation and signaling.
Source: US FDA prescribing information
Initiate dosing with 10 mg/kg for first infusion, followed by 20 mg/kg every 3 weeks for 7 additional infusions. Administer TEPEZZA by intravenous infusion over 60 to 90 minutes
Source: US FDA prescribing information
None. None
Source: US FDA prescribing information
Infusion Reactions: If an infusion reaction occurs, interrupt or slow the rate of infusion and use appropriate medical management. Inflammatory Bowel Disease (IBD): Monitor patients, for signs and symptoms of disease, including patients without a history of IBD, discontinue TEPEZZA if IBD exacerbation is suspected. Hyperglycemia: Assess patients for elevated blood glucose and symptoms of hyperglycemia prior to infusion and continue to monitor while on treatment with TEPEZZA. Ensure patients with hyperglycemia or preexisting diabetes are under appropriate glycemic control before and while receiving TEPEZZA. Hearing Impairment Including Hearing Loss: TEPEZZA may cause severe hearing impairment including hearing loss, which in some cases may be permanent. Assess patients' hearing before, during, and after treatment with TEPEZZA and consider the benefit-risk of treatment with patients.
Source: US FDA prescribing information
The following clinically significant adverse reactions are described elsewhere in the labeling: Infusion Reactions Inflammatory Bowel Disease Hyperglycemia Hearing Impairment Including Hearing Loss Most common adverse reactions (incidence greater than 5%) are muscle spasm, nausea, alopecia, diarrhea, fatigue, hyperglycemia, hearing impairment, dry skin, dysgeusia, headache, weight decreased, and nail disorder
Source: US FDA prescribing information
Refrigerate at 2°C to 8°C (36°F to 46°F) in original carton until time of use to protect from light. Do not freeze.
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
1 presentations of Teprotumumab, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Tepezza 500 mg powder for injectionIntravenous Cold chain | Horizon Therapeutics | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
Yes, on request. MedsAcross lists 1 presentations of Teprotumumab and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Teprotumumab, including Tepezza.
Yes. The US FDA first approved Teprotumumab on 21 January 2020, according to Drugs@FDA.
Yes. Teprotumumab has a central EU marketing authorisation (status: authorised), according to European Medicines Agency data.
At least one listed presentation of Teprotumumab must be kept cold, so it is shipped in temperature-controlled packaging. Check the storage line on each presentation.
Teprotumumab is classified under ATC code L04AG13 (Teprotumumab).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.